Calliditas intends to commercialize Nefecon for IgA nephropathy on a standalone basis in the United States and most likely through partnerships in other regions.
For further information or to discuss new opportunities, please contact: email@example.com.
Please email our business development team for any business enquiries.
Email us: firstname.lastname@example.org
Calliditas Therapeutics AB
PO Box 70351
SE-10724 Stockholm, Sweden